Perifosine (KRX-0401)
| Brand Name: | |
| Generic Name: | perifosine |
| Code Name: | KRX-0401 |
| Company: | Keryx Biopharmaceuticals / Aeterna Zentaris |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Perifosine (news articles) is a novel anti-cancer agent that is being studied for its ability to inhibit Akt, a key signal transduction pathway. Akt is particularly important in the development of cancers, impacting programmed cell death, cell growth, cell differentiation, and cell survival. High levels of activated Akt are frequently observed in many types of cancer, and it is often activated in tumors that are resistant to other anti-cancer therapy. Perifosine does not appear to cause flu-like symptoms, decreases in platelets, or hair loss, which distinguishes it from other novel agents that inhibit the Akt pathway. The most common side effects include nausea, vomiting, diarrhea, and fatigue.
Clinical Trials:
For a list of clinical trials studying perifosine for the treatment of multiple myeloma, see ClinicalTrials.gov.
Web site for Perifosine: http://www.keryx.com/page.cfm?hmid=20&smid=30&pg=19
Related Articles:
- Selective Digestive Decontamination May Reduce Risk of Infection In Myeloma Patients Undergoing Autologous Stem Cell Transplants
- Nelfinavir Shows Only Limited Success In Overcoming Revlimid Resistance In Multiple Myeloma Patients
- Getting To Know: Tiragolumab
- Nelfinavir-Velcade Combination Very Active In Advanced, Velcade-Resistant Multiple Myeloma
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
Keryx Pharmaceuticals has rights to distribute Perifosine in the U.S. and Canada. It is actually a product of Aeterna Zentaris (AEZS).